Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Chinese

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2020, Vol. 25 ›› Issue (8): 878-889.doi: 10.12092/j.issn.1009-2501.2020.08.006

Previous Articles     Next Articles

Comparison of policies and guidelines regarding using of real world data/real word evidence

WANG Minhui1, ZHAO Yang3, DENG Yazhong4, XUE Fubo5, XIE Haitang1, YAO Chen2   

  1. 1 Yijishan Hospital of Wannan Medical College, Wuhu 241000, Anhui, China; 2 Peking University First Hospital, Beijing 100034, China; 3 Nanjing Medical University, Nanjing 211166, Jiangsu, China; 4 Beijing Trust Medicine Consulting Ltd., Beijing 100089, China; 5 TopAlliance Biosciences Inc., Shanghai 201203, China
  • Received:2020-04-03 Revised:2020-05-26 Online:2020-08-26 Published:2020-09-03

Abstract: China and foreign regulators have conducted multiple discussions on how to use Real World Data (RWD) and Real World Evidence (RWE), also published relevant guidelines and framework files. The development and promotion of RWD/RWE application in China is relatively late, and there is a gap of systems and conditions between China and developed countries. This article aims to learn from advantage experiences of other countries and provide some referential ideas for exploring a strategy of RWD/RWE applications suitable for China by analyzing and comparing the current RWD/RWE application-related policies and guidelines in different regions.

Key words: real world data, real world evidence, real world study, policy, guideline

CLC Number: